RxDoctor Payments DataLook up a doctor →

Abha Mishra, MD

Neurology · Gulfport, MSNPI 1285668921

Payments from drug & device makers

$12,029in general payments, 2019–2025

Across 446 payments — averaging $26.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$7K
  • Novartis$826
  • Amgen$657
  • Pfizer$467
  • UCB, Inc.$372
  • Acadia Pharmaceuticals Inc$276
  • plus $3K from 36 others

What the payments were for

  • Speaking & faculty fees$3,90032%
  • Travel & lodging$6295%
  • Food & beverage$7,50062%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,029 in reported general payments places this provider in the 70th percentile of 111 neurology providers in Mississippi.

See all neurology providers in Mississippi

Medicare billing

Part B allowed, 2024
$430,447
Medicare patients
1,371
Services billed
3,407

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5030$803,633
OctagamImmun Globg(Igg)/Malt/Iga Ov5030$677,089
UltomirisRavulizumab-Cwvz12$559,943
TecfideraDimethyl Fumarate13$120,966
UbrelvyUbrogepant58$92,063
Teriflunomide14$87,787
QuliptaAtogepant46$59,755
Nurtec OdtRimegepant Sulfate39$52,779
Glatiramer Acetate21$50,538
Aimovig AutoinjectorErenumab-Aooe42$37,349
FycompaPerampanel14$34,276
BotoxOnabotulinumtoxina19$33,376
VimpatLacosamide19$28,083
Pyridostigmine Bromide ErPyridostigmine Bromide19$24,750
NamzaricMemantine Hcl/Donepezil Hcl18$17,990

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringPrivigen$38$803,63330 claims
PfizerOctagam, Nurtec Odt$467$729,86869 claims
AstraZenecaUltomiris$180$559,94312 claims
AbbVieUbrelvy, Qulipta, Botox, Namzaric$6,741$203,184141 claims
BiogenTecfidera$26$120,96613 claims
UCB, Inc.Vimpat$372$28,08319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 111 neurology providers in Mississippi.

Other neurology in Gulfport

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →